donor bone marrow infusion and a 1-month course of cyclosporine), we found no thromboembolic complications in more than 50 animals. In contrast, after adding 20 mg/kg of monoclonal antibody ...

The global infusion devices market is observing significant growth owing to the increasing prevalence of cancer and strategic ...

Fact checked by Nick Blackmer The recent approvals of Leqembi (lecanemab) and Kisunla (donanemab) have refreshed the ...

It is expensive - a potent intravenous infusion of antibodies to neutralise the virus, rather than dampen the body's inflammatory response to it. Results from the Recovery trial suggest it could ...

Eculizumab, a monoclonal antibody, is indicated for the treatment of two rare and life-threatening conditions: Paroxysmal ...